LONDON (Alliance News) - Summit Therapeutics PLC said Thursday that it has completed enrolment for its Phase II proof-of-concept trial of SMT19969 for the treatment of Clostridium difficile infection.
The company said that patient dosing and follow-up is continuing, and top-line results are expected in the fourth quarter of 2015.
"CDI is now widely accepted to be a major healthcare issue, and with current antibiotics used to treat CDI having high rates of disease recurrence, there is an urgent need to develop new therapies," said Chief Executive Officer Glyn Edwards in a statement.
"We believe SMT19969 represents an important advance as its potency in killing C. difficile bacteria is complemented by selective targeting that leaves the healthy gut microbiome unharmed," Edwards added.
Shares in Summit Therapeutics were up 0.4% at 151.65 pence Thursday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
